treatment of pediatric chronic immune thrombocytopenic purpura

• European Union
• Healthcare
• Pharma & Biotech
• Switzerland

Novartis: European Commission (EC) approved Revolade® for treatment of pediatric chronic immune thrombocytopenic purpura (ITP) patients

EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have…